Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort

被引:92
|
作者
Lacey, James V., Jr. [1 ]
Kreimer, Aimee R. [2 ,3 ]
Buys, Saundra S. [4 ]
Marcus, Pamela M. [5 ]
Chang, Shih-Chen [6 ,7 ]
Leitzmann, Michael F. [7 ,8 ]
Hoover, Robert N. [9 ]
Prorok, Philip C. [5 ]
Berg, Christine D. [2 ]
Hartge, Patricia [9 ]
机构
[1] NCI, Hormonal & Reprod Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[2] NIH, Early Detect Res Grp, Canc Prevent Div, Rockville, MD USA
[3] NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[4] Univ Utah, Dept Internal Med, Huntsman Canc Inst, Hlth Sci Ctr, Salt Lake City, UT 84112 USA
[5] NCI, Biometry Res Grp, Canc Prevent Div, NIH, Rockville, MD USA
[6] AstraZeneca, Global Epidemiol Dept, Wilmington, DE USA
[7] NCI, Nutr Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
[8] Univ Regensburg, Inst Epidemiol & Prevent Med, Regensburg, Germany
[9] NCI, Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA
关键词
AGE; WOMEN; MENOPAUSE; GENOME; BIRTH; ASSOCIATION; MENARCHE; GENES; MODEL; FAT;
D O I
10.1186/1471-2407-9-84
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Multidisciplinary attempts to understand the etiology of breast cancer are expanding to increasingly include new potential markers of disease risk. Those efforts may have maximal scientific and practical influence if new findings are placed in context of the well-understood lifestyle and reproductive risk factors or existing risk prediction models for breast cancer. We therefore evaluated known risk factors for breast cancer in a cancer screening trial that does not have breast cancer as a study endpoint but is large enough to provide numerous analytic opportunities for breast cancer. Methods: We evaluated risk factors for breast cancer (N = 2085) among 70,575 women who were randomized in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Using Poisson regression, we calculated adjusted relative risks [RRs, with 95% confidence intervals (CIs)] for lifestyle and reproductive factors during an average of 5 years of follow-up from date of randomization. Results: As expected, increasing age, nulliparity, positive family history of breast cancer, and use of menopausal hormone therapy were positively associated with breast cancer. Later age at menarche (16 years or older vs. < 12: RR = 0.81, 95% CI, 0.65-1.02) or menopause (55 years or older vs. < 45: RR = 1.29, 95% CI, 1.03-1.62) were less strongly associated with breast cancer than was expected. There were weak positive associations between taller height and heavier weight, and only severe obesity [ body mass index (BMI; kg/m(2)) 35 or more vs. 18.5-24.9: RR = 1.21, 95% CI, 1.02-1.43] was statistically significantly associated with breast cancer. Conclusion: The ongoing PLCO trial offers continued opportunities for new breast cancer investigations, but these analyses suggest that the associations between breast cancer and age at menarche, age at menopause, and obesity might be changing as the underlying demographics of these factors change.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Measuring the impact of HIPAA in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
    Marcus, PM
    Miedzinksi, M
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (02) : 549 - 549
  • [42] Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial
    Miller, AB
    Yurgalevitch, S
    Weissfeld, JL
    [J]. CONTROLLED CLINICAL TRIALS, 2000, 21 (06): : 400S - 406S
  • [43] The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource
    Zhu, Claire S.
    Huang, Wen-Yi
    Pinsky, Paulf F.
    Berg, Christine D.
    Sherman, Mark
    Yu, Kelly J.
    Carrick, Danielle M.
    Black, Amanda
    Hoover, Robert
    Lenz, Petra
    Williams, Craig
    Hawkins, Laura
    Chaloux, Matthew
    Yurgalevitch, Susan
    Mathew, Sunitha
    Miller, Amy
    Olivo, Vanessa
    Khan, Asia
    Pretzel, Shannon M.
    Multerer, Deborah
    Beckmann, Patricia
    Broski, Karen G.
    Freedman, Neal D.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (12) : 1635 - 1642
  • [44] Determinants of radical prostatectomy in the prostate, lung, colorectal, ovarian (PLCO) cancer screening trial
    Miller, David C.
    Church, Timothy R.
    Hickey, Thomas
    Greenlee, Robert T.
    Lzmirlian, Grant
    Mabie, Jerome
    Riley, Thomas L.
    Ragard, Lawrence
    Prorok, Philip C.
    Berg, Christine D.
    Crawford, E. David
    Andriole, Gerald L.
    Grubb, Robert L.
    [J]. JOURNAL OF UROLOGY, 2008, 179 (04): : 29 - 29
  • [45] Prediagnostic Serum Levels of Fatty Acid Metabolites and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Hada, Manila
    Edin, Matthew L.
    Hartge, Patricia
    Lih, Fred B.
    Wentzensen, Nicolas
    Zeldin, Darryl C.
    Trabert, Britton
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2019, 28 (01) : 189 - 197
  • [46] Effectiveness of nurse endoscopists in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial
    Bresalier, RS
    Pinsky, P
    Weissfeld, J
    Schoen, R
    Church, T
    Yokochi, L
    Prorok, P
    [J]. GASTROENTEROLOGY, 2002, 122 (04) : A479 - A479
  • [47] Prostate cancer screening in the prostate, lung, colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial
    Andriole, GL
    Levin, DL
    Crawford, ED
    Gelmann, ER
    Pinsky, PF
    Chia, D
    Kramer, BS
    Reding, D
    Church, TR
    Grubb, RL
    Izmirlian, G
    Ragard, LR
    Clapp, JD
    Prorok, PC
    Gohagan, JK
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (06) : 433 - 438
  • [48] Serum vitamin D and risk of prostate cancer among black men in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Layne, Tracy M.
    Weinstein, Stephanie
    Ma, Xiaomei
    Graubard, Barry I.
    Mayne, Susan T.
    Albanes, Demetrius
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (03)
  • [49] Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
    Freedman, D. Michal
    Chang, Shih-Chen
    Falk, Roni T.
    Purdue, Mark P.
    Huang, Wen-Yi
    McCarty, Catherine A.
    Hollis, Bruce W.
    Graubard, Barry I.
    Berg, Christine D.
    Ziegler, Regina G.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (04) : 889 - 894
  • [50] Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
    Stolzenberg-Solomon, RZ
    Chang, SC
    Leitzmann, MF
    Johnson, KA
    Johnson, C
    Buys, SS
    Hoover, RN
    Ziegler, RG
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2006, 83 (04): : 895 - 904